You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Namegabapentin enacarbil
Accession NumberDB08872
TypeSmall Molecule
GroupsApproved
DescriptionGabapentin enacarbil is marketed under the name Horizant®. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Structure
Thumb
Synonyms
Gabapentina enacarbilo
Gabapentine enacarbil
Gabapentinum enacarbilum
Horizant
XP 13512
XP-13512
XP13512
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HorizantTablet, extended release600 mg/1OralXeno Port Inc.2013-05-01Not applicableUs
HorizantTablet, extended release300 mg/1OralXeno Port Inc.2013-05-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII75OCL1SPBQ
CAS number478296-72-9
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Structured Indications
PharmacodynamicsSince gabapentin enacarbil is a prodrug of gabapentin, it's physiological effects are the same as gabapentin. Concerning PHN, gabapentin prevents allodynia and hyperalgesia.
Mechanism of actionAlthough the exact mechanism of action of gabapentin in RLS and PHN is unknown, it is presumed to involve the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors.
Related Articles
AbsorptionGabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1.
Volume of distribution

The volume of distribution is 76L.

Protein bindingGabapentin plasma protein binding is less than 3%.
Metabolism

Gabapentin enacarbil does not interact with any of the major cytochrome P450 enzymes.

Route of eliminationGabapentin enacarbil is eliminated primarily in the urine (94%) and to a lesser extent in the feces (5%).
Half lifeThe elimination half-life of gabapentin is 5.1 to 6.0 hours.
Clearance

Renal clearance of gabapentin is 5 to 7 L/hr.

ToxicityMost common adverse reactions are headache, dizziness, and somnolence.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with gabapentin enacarbil.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with gabapentin enacarbil.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with gabapentin enacarbil.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with gabapentin enacarbil.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with gabapentin enacarbil.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with gabapentin enacarbil.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with gabapentin enacarbil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with gabapentin enacarbil.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with gabapentin enacarbil.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with gabapentin enacarbil.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with gabapentin enacarbil.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with gabapentin enacarbil.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with gabapentin enacarbil.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with gabapentin enacarbil.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with gabapentin enacarbil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with gabapentin enacarbil.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with gabapentin enacarbil.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with gabapentin enacarbil.Vet Approved
Azelastinegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with gabapentin enacarbil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with gabapentin enacarbil.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with gabapentin enacarbil.Illicit
BenperidolThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with gabapentin enacarbil.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with gabapentin enacarbil.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with gabapentin enacarbil.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with gabapentin enacarbil.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with gabapentin enacarbil.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with gabapentin enacarbil.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with gabapentin enacarbil.Approved, Investigational
Buprenorphinegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with gabapentin enacarbil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with gabapentin enacarbil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with gabapentin enacarbil.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with gabapentin enacarbil.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with gabapentin enacarbil.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with gabapentin enacarbil.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with gabapentin enacarbil.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with gabapentin enacarbil.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with gabapentin enacarbil.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with gabapentin enacarbil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with gabapentin enacarbil.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with gabapentin enacarbil.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with gabapentin enacarbil.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with gabapentin enacarbil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with gabapentin enacarbil.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with gabapentin enacarbil.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with gabapentin enacarbil.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with gabapentin enacarbil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with gabapentin enacarbil.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with gabapentin enacarbil.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with gabapentin enacarbil.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with gabapentin enacarbil.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with gabapentin enacarbil.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with gabapentin enacarbil.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with gabapentin enacarbil.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with gabapentin enacarbil.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with gabapentin enacarbil.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with gabapentin enacarbil.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with gabapentin enacarbil.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with gabapentin enacarbil.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with gabapentin enacarbil.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with gabapentin enacarbil.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with gabapentin enacarbil.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with gabapentin enacarbil.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with gabapentin enacarbil.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with gabapentin enacarbil.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with gabapentin enacarbil.Approved
DapoxetineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with gabapentin enacarbil.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with gabapentin enacarbil.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with gabapentin enacarbil.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with gabapentin enacarbil.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with gabapentin enacarbil.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with gabapentin enacarbil.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with gabapentin enacarbil.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with gabapentin enacarbil.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with gabapentin enacarbil.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with gabapentin enacarbil.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with gabapentin enacarbil.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with gabapentin enacarbil.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with gabapentin enacarbil.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with gabapentin enacarbil.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with gabapentin enacarbil.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with gabapentin enacarbil.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with gabapentin enacarbil.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with gabapentin enacarbil.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with gabapentin enacarbil.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with gabapentin enacarbil.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with gabapentin enacarbil.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with gabapentin enacarbil.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with gabapentin enacarbil.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with gabapentin enacarbil.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with gabapentin enacarbil.Experimental
EcopipamThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with gabapentin enacarbil.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with gabapentin enacarbil.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with gabapentin enacarbil.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with gabapentin enacarbil.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with gabapentin enacarbil.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with gabapentin enacarbil.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with gabapentin enacarbil.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with gabapentin enacarbil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with gabapentin enacarbil.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with gabapentin enacarbil.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with gabapentin enacarbil.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with gabapentin enacarbil.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with gabapentin enacarbil.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with gabapentin enacarbil.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with gabapentin enacarbil.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with gabapentin enacarbil.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with gabapentin enacarbil.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with gabapentin enacarbil.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with gabapentin enacarbil.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with gabapentin enacarbil.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with gabapentin enacarbil.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with gabapentin enacarbil.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with gabapentin enacarbil.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with gabapentin enacarbil.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with gabapentin enacarbil.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with gabapentin enacarbil.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with gabapentin enacarbil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with gabapentin enacarbil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with gabapentin enacarbil.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with gabapentin enacarbil.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with gabapentin enacarbil.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with gabapentin enacarbil.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with gabapentin enacarbil.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with gabapentin enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with gabapentin enacarbil.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with gabapentin enacarbil.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with gabapentin enacarbil.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with gabapentin enacarbil.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with gabapentin enacarbil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with gabapentin enacarbil.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with gabapentin enacarbil.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with gabapentin enacarbil.Approved
Hydrocodonegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with gabapentin enacarbil.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with gabapentin enacarbil.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with gabapentin enacarbil.Approved
IndalpineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with gabapentin enacarbil.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with gabapentin enacarbil.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with gabapentin enacarbil.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with gabapentin enacarbil.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with gabapentin enacarbil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with gabapentin enacarbil.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with gabapentin enacarbil.Approved
LevocabastineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with gabapentin enacarbil.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with gabapentin enacarbil.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with gabapentin enacarbil.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with gabapentin enacarbil.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with gabapentin enacarbil.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with gabapentin enacarbil.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with gabapentin enacarbil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with gabapentin enacarbil.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with gabapentin enacarbil.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with gabapentin enacarbil.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with gabapentin enacarbil.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with gabapentin enacarbil.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with gabapentin enacarbil.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with gabapentin enacarbil.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with gabapentin enacarbil.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with gabapentin enacarbil.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with gabapentin enacarbil.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with gabapentin enacarbil.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with gabapentin enacarbil.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with gabapentin enacarbil.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with gabapentin enacarbil.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with gabapentin enacarbil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with gabapentin enacarbil.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with gabapentin enacarbil.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with gabapentin enacarbil.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with gabapentin enacarbil.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with gabapentin enacarbil.Approved
Methotrimeprazinegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with gabapentin enacarbil.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with gabapentin enacarbil.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with gabapentin enacarbil.Approved
Metyrosinegabapentin enacarbil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with gabapentin enacarbil.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Investigational
Mirtazapinegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with gabapentin enacarbil.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with gabapentin enacarbil.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with gabapentin enacarbil.Approved
NefazodoneThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with gabapentin enacarbil.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with gabapentin enacarbil.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with gabapentin enacarbil.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with gabapentin enacarbil.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with gabapentin enacarbil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with gabapentin enacarbil.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with gabapentin enacarbil.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with gabapentin enacarbil.Approved, Illicit
Orphenadrinegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with gabapentin enacarbil.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with gabapentin enacarbil.Approved
OxetacaineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with gabapentin enacarbil.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with gabapentin enacarbil.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with gabapentin enacarbil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with gabapentin enacarbil.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with gabapentin enacarbil.Approved
Paraldehydegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with gabapentin enacarbil.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with gabapentin enacarbil.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
PerazineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with gabapentin enacarbil.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with gabapentin enacarbil.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with gabapentin enacarbil.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with gabapentin enacarbil.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with gabapentin enacarbil.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with gabapentin enacarbil.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with gabapentin enacarbil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with gabapentin enacarbil.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with gabapentin enacarbil.Approved
PiritramideThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with gabapentin enacarbil.Approved
PomalidomideThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Pomalidomide.Approved
Pramipexolegabapentin enacarbil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with gabapentin enacarbil.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with gabapentin enacarbil.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with gabapentin enacarbil.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with gabapentin enacarbil.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with gabapentin enacarbil.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with gabapentin enacarbil.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with gabapentin enacarbil.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with gabapentin enacarbil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with gabapentin enacarbil.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with gabapentin enacarbil.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with gabapentin enacarbil.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with gabapentin enacarbil.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with gabapentin enacarbil.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with gabapentin enacarbil.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with gabapentin enacarbil.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with gabapentin enacarbil.Approved
RacloprideThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with gabapentin enacarbil.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with gabapentin enacarbil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with gabapentin enacarbil.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with gabapentin enacarbil.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with gabapentin enacarbil.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with gabapentin enacarbil.Vet Approved
Ropinirolegabapentin enacarbil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with gabapentin enacarbil.Approved
Rotigotinegabapentin enacarbil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with gabapentin enacarbil.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with gabapentin enacarbil.Experimental
Sage 547The risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with gabapentin enacarbil.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with gabapentin enacarbil.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with gabapentin enacarbil.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with gabapentin enacarbil.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
StiripentolThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with gabapentin enacarbil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with gabapentin enacarbil.Approved
Suvorexantgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with gabapentin enacarbil.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with gabapentin enacarbil.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with gabapentin enacarbil.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with gabapentin enacarbil.Investigational
Thalidomidegabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with gabapentin enacarbil.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with gabapentin enacarbil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with gabapentin enacarbil.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with gabapentin enacarbil.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with gabapentin enacarbil.Approved
TiaprideThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with gabapentin enacarbil.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with gabapentin enacarbil.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with gabapentin enacarbil.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with gabapentin enacarbil.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with gabapentin enacarbil.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with gabapentin enacarbil.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with gabapentin enacarbil.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with gabapentin enacarbil.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with gabapentin enacarbil.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with gabapentin enacarbil.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with gabapentin enacarbil.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with gabapentin enacarbil.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with gabapentin enacarbil.Approved
Uc1010The risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with gabapentin enacarbil.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with gabapentin enacarbil.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with gabapentin enacarbil.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with gabapentin enacarbil.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with gabapentin enacarbil.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with gabapentin enacarbil.Approved
ZimelidineThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with gabapentin enacarbil.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with gabapentin enacarbil.Vet Approved
Zolpidemgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with gabapentin enacarbil.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with gabapentin enacarbil.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with gabapentin enacarbil.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with gabapentin enacarbil.Approved, Investigational
Food Interactions
  • No food effects.
References
Synthesis Reference

1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14.

General References
  1. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14. [PubMed:15146029 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (347 KB)
MSDSDownload (30.7 KB)
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral600 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6818787 No2002-11-062022-11-06Us
US8026279 No2006-11-102026-11-10Us
US8048917 No2002-11-062022-11-06Us
US8114909 No2006-04-112026-04-11Us
US8686034 No2005-01-242025-01-24Us
US8795725 No2009-06-102029-06-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointMelting onset of about 64°C.From FDA label.
water solubilitySolubility of 0.5 mg/mL in water From FDA label.
pKapKa 5.0From The Merck Index.
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Symporter activity
Specific Function:
Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate ...
Gene Name:
SLC5A8
Uniprot ID:
Q8N695
Molecular Weight:
66577.005 Da
References
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. [PubMed:15146028 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Sodium-dependent multivitamin transmembrane transporter activity
Specific Function:
Transports pantothenate, biotin and lipoate in the presence of sodium.
Gene Name:
SLC5A6
Uniprot ID:
Q9Y289
Molecular Weight:
68641.27 Da
References
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. [PubMed:15146028 ]
Comments
comments powered by Disqus
Drug created on May 02, 2013 15:20 / Updated on December 09, 2016 02:39